Medical and non-medical Cannabis use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization
Bahorik et al.·Journal of Affective DisordersImpact 4.3
SchadenGRADEHoch55 Zitate
Stichproben = 307 Pat.
Dauer12 Monate
KontrolleKein Cannabiskonsum
EndpunktSuizidideation /…
Verblindungunklar
DesignRCT
”Kernaussage
Non-medizinische Cannabisnutzung war mit höherer Suizidideation, schlechterer psychischer Funktionalität, weniger psychiatrischen Besuchen und geringerer Verbesserung der Depressionssymptome über Zeit assoziiert.
Zusammenfassung
Prospektive Kohortenstudie bei n=307 ambulanten Depressionspatienten über 12 Monate; 40% Cannabis-Konsum (71,7% nicht-medizinisch, 28,2% medizinisch). Nicht-medizinischer Konsum assoziiert mit höherer Suizidalität zu Baseline (B=1,08, p=0,002), schlechterer mentaler Funktionsfähigkeit (B=-3,79, p=0,015) und weniger Psychiatrie-Besuchen (B=-0,69, p=0,009). Über Zeit geringere Verbesserung bei Depressionssymptomen (B=1,49, p=0,026) und Suizidalität (B=1,08, p=0,003) vs. Nicht-Nutzer.
P
PopulationPsychiatrische Ambulanzpatienten mit Depression und Substanzgebrauch, n=307
I
InterventionMedizinischer oder nicht-medizinischer Cannabiskonsum (selbstberichtet, vergangene 30 Tage)
C
KontrolleKein Cannabiskonsum (Referenzgruppe)
O
OutcomeNicht-medizinischer Konsum assoziiert mit höherer Suizidideation (B=1,08; p=0,002), schlechterer psychischer Funktionsfähigkeit (B=-3,79; p=0,015) und weniger Psychiatriebesuchen (B=-0,69; p=0,009); über die Zeit geringere Verbesserung in Depressionssymptomatik (B=1,49; p=0,026) und Suizidideation (B=1,08; p=0,003) vs. Nicht-Konsumierende
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Background: Cannabis use is clinically problematic in depression, and non-medical and medical use may both contribute to barriers to care in this population. Among outpatients with depression, we examined the differential impact of medical or non-medical Cannabis use, relative to no-use, on psychopathology and service use over time.
Method: Participants were 307 psychiatry outpatients participating in a trial of drug/alcohol use treatment for depression. Measures of past 30-day Cannabis use, depression/anxiety symptoms, psychiatry visits, and functional data related to health status were collected at baseline, 3, 6, and 12 months. Regressions (baseline and 1 year) and growth models (over time) predicted clinical and psychiatry visit outcomes, from medical or non-medical Cannabis use (no-use = reference).
Results: At baseline, 40.0% of the sample used Cannabis and more reported non-medical (71.7%) than medical (28.2%) use. Relative to non-users at baseline, patients using medically had worse mental/physical health functioning (p's < 0.05), and non-medical use was associated with higher suicidal ideation (B = 1.08, p = .002), worse mental health functioning (B = -3.79, p = .015), and fewer psychiatry visits (B = -0.69, p = .009). Patients using non-medically over time improved less in depression symptoms (B = 1.49, p = .026) and suicidal ideation (B = 1.08, p = .003) than non-users.
Limitations: Participants were psychiatry outpatients, limiting generalizability.
Conclusions: Cannabis use, especially non-medical use, among patients with depression may impede depression symptom improvement while lessening the likelihood of psychiatry visits. Cannabis use and associated barriers to care should receive consideration by depression treatment providers.